LabCorp announces 2020 third quarter results

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 27, 2020-- LabCorp (or the Company) (NYSE: LH) today announced results for the third quarter ended September 30, 2020.

LabCorp transforms the clinical trial experience and streamlines the drug development process

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 20, 2020-- LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, today announced new capabilities that will transform the clinical trial experience with the goal of streamlining the drug development process. This transformation will enable LabCorp’s drug development business, Covance, a global leader in decentralized clinical trials (DCTs), to quickly and efficiently connect patients to clinical trials, which will allow for better access to potential drugs, vaccines, and medical devices. Additionally, the seamless, tech-enabled, patient-centric capabilities will provide a better clinical trial experience for patients, and biopharmaceutical and medical device customers.

LabCorp and Swedish extend laboratory services relationship, providing continued access to high-quality diagnostics and COVID-19 testing

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 19, 2020-- LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, and Swedish, the largest nonprofit healthcare system in the Puget Sound region, today announced an agreement to extend their more than 20-year relationship.

LabCorp launches quantitative antibody test to assess effectiveness of COVID-19 vaccines in clinical trials

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 19, 2020-- LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care, today announced a test that provides a quantitative measurement of an individual’s SARS-CoV-2 IgG antibodies. LabCorp’s Cov2Quant™ IgG test, which is available only for use in clinical trials and research, was developed to specifically detect and quantify antibodies to SARS-CoV-2, the virus that causes COVID-19. The level of antibodies is an important indicator of the strength of a person’s immune response, which can help determine the effectiveness of vaccines and therapies.

LabCorp is first to provide consumers with secure access to their diagnostic test results through CommonHealth

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 13, 2020-- LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, and The Commons Project , a non-profit public trust dedicated to building global digital services and platforms for the common good, today announced a strategic partnership to allow people to securely access their LabCorp test results via CommonHealth, the privacy-preserving Android app that enables users to safely collect, store, and use their personal health information. LabCorp is the first major commercial lab to integrate with CommonHealth, which is also working with a wide range of other health care providers.